Related Experiment Video
Updated: May 18, 2026
07:25
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Are novel combination therapies needed for chronic hepatitis B?
1INSERM U1052, UMR CNRS 5268, Cancer Research Center of Lyon, F-69003 Lyon, France. fabien.zoulim@inserm.fr
Antiviral Research
|September 25, 2012
Summary
Current chronic hepatitis B treatments offer limited HBeAg seroconversion and HBsAg loss. New antiviral drug targets are being investigated to improve therapy response and reduce long-term complications.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis B (CHB) treatment relies on monotherapy with pegInterferon-alpha or nucleoside analogues (NUCs).
- While NUCs achieve high viral suppression rates (approx. 95%), they yield low rates of HBeAg seroconversion (20%) and HBsAg loss (10% after 5 years).
- Combination therapies with existing drugs have proven unsuccessful in improving outcomes.
Purpose of the Study:
- To explore novel therapeutic targets within the Hepatitis B Virus (HBV) replication cycle.
- To identify new antiviral compounds for CHB treatment.
- To enhance treatment efficacy beyond current monotherapies.
Main Methods:
- Investigation of multiple steps in the HBV replication cycle.
- Evaluation of novel drug targets and compounds.
- Utilizing in vitro and in vivo models of HBV infection for assessment.
Main Results:
- Current therapies demonstrate limited efficacy in achieving functional cure (HBsAg loss) and HBeAg seroconversion.
- Combination strategies using existing drugs have not improved patient outcomes.
- Research is actively pursuing new targets to overcome these limitations.
Conclusions:
- Novel therapeutic strategies targeting the HBV lifecycle are essential for improving treatment outcomes.
- New antiviral drugs hold the potential to significantly increase response rates.
- Improved therapies could reduce the incidence of drug resistance, cirrhosis, and hepatocellular carcinoma.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...